Triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib for RRMM

According to phase-I/IIa findings from the ANCHOR (OP-104) trial that were introduced during the second EMN (European Myeloma Network) Meeting, […]